Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    October 2017
  1. FIGUEIRA MI, Cardoso HJ, Correia S, Maia CJ, et al
    The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?
    Cancer Lett. 2017;405:10-21.
    PubMed     Text format     Abstract available


    September 2017
  2. AL-MATOUQ J, Holmes T, Hammiller B, Tran N, et al
    Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
    Cancer Lett. 2017 Sep 23. pii: S0304-3835(17)30573.
    PubMed     Text format     Abstract available


  3. AIDA S, Sonobe Y, Tanimura H, Oikawa N, et al
    MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30555.
    PubMed     Text format     Abstract available


  4. HUANG GX, Wang Y, Su J, Zhou P, et al
    Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30552.
    PubMed     Text format     Abstract available


  5. WANG S, Zhou R, Sun F, Li R, et al
    The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30551.
    PubMed     Text format     Abstract available


    August 2017
  6. QIN H, Liu X, Li F, Miao L, et al
    PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30506.
    PubMed     Text format     Abstract available


  7. WANG B, Zhao H, Zhao L, Zhang Y, et al
    Up-regulation of OLR1 expression by TBC1D3 through activation of TNFalpha/NF-kappaB pathway promotes the migration of human breast cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30508.
    PubMed     Text format     Abstract available


  8. FALLATAH M, Liu S, Sevigny MB, Zou H, et al
    Novel flexible heteroarotinoid, SL-1-18, promotes ERalpha degradation to inhibit breast cancer cell growth.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30513.
    PubMed     Text format     Abstract available


  9. RUZZOLINI J, Peppicelli S, Andreucci E, Bianchini F, et al
    Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30487.
    PubMed     Text format     Abstract available


  10. AMUNJELA JN, Tucker SJ
    POPDC1 is suppressed in human breast cancer tissues and is negatively regulated by EGFR in breast cancer cell lines.
    Cancer Lett. 2017;406:81-92.
    PubMed     Text format     Abstract available


  11. WANG J, Hirose H, Du G, Chong K, et al
    P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
    Cancer Lett. 2017 Aug 10. pii: S0304-3835(17)30478.
    PubMed     Text format     Abstract available


  12. LI L, Kang L, Zhao W, Feng Y, et al
    miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect.
    Cancer Lett. 2017;400:89-98.
    PubMed     Text format     Abstract available


    July 2017
  13. CALERO R, Morchon E, Martinez-Argudo I, Serrano R, et al
    Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Cancer Lett. 2017 Jul 31. pii: S0304-3835(17)30457.
    PubMed     Text format     Abstract available


  14. PERES J, Maliepaard EM, Rambow F, Larue L, et al
    The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
    Cancer Lett. 2017 Jul 28. pii: S0304-3835(17)30454.
    PubMed     Text format     Abstract available


  15. CIMAS FJ, Callejas-Valera JL, Garcia-Olmo DC, Hernandez-Losa J, et al
    E1a is an exogenous in vivo tumour suppressor.
    Cancer Lett. 2017;399:74-81.
    PubMed     Text format     Abstract available


  16. BORST A, Haferkamp S, Grimm J, Rosch M, et al
    Involvement of the BH3-only pro-apoptotic BIK/NBK in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Cancer Lett. 2017 Jul 15. pii: S0304-3835(17)30431.
    PubMed     Text format     Abstract available


  17. KUZU OF, Gowda R, Sharma A, Noory MA, et al
    Improving Pharmacological Targeting of AKT in Melanoma.
    Cancer Lett. 2017 Jul 10. pii: S0304-3835(17)30419.
    PubMed     Text format     Abstract available


  18. CALAPRE L, Warburton L, Milward M, Ziman M, et al
    Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Cancer Lett. 2017 Jul 4. pii: S0304-3835(17)30412.
    PubMed     Text format     Abstract available


  19. LI Y, Cai B, Shen L, Dong Y, et al
    MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3.
    Cancer Lett. 2017;397:111-119.
    PubMed     Text format     Abstract available


    June 2017
  20. HALLDORSSON S, Rohatgi N, Magnusdottir M, Choudhary KS, et al
    Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition.
    Cancer Lett. 2017;396:117-129.
    PubMed     Text format     Abstract available


  21. LEE YK, Park UH, Kim EJ, Hwang JT, et al
    Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Cancer Lett. 2017 Jun 17. pii: S0304-3835(17)30396.
    PubMed     Text format     Abstract available


    May 2017
  22. YU ZH, Lun SM, He R, Tian HP, et al
    The dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Suppression of progression but promotion of proliferation.
    Cancer Lett. 2017 May 31. pii: S0304-3835(17)30356.
    PubMed     Text format     Abstract available


    April 2017
  23. WANG Y, Liu M, Jin Y, Jiang S, et al
    In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30289.
    PubMed     Text format     Abstract available


  24. WU YH, Hong CW, Wang YC, Huang WJ, et al
    A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Cancer Lett. 2017 Apr 24. pii: S0304-3835(17)30283.
    PubMed     Text format     Abstract available


  25. LUI AJ, Geanes ES, Ogony J, Behbod F, et al
    IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
    Cancer Lett. 2017 Apr 12. pii: S0304-3835(17)30235.
    PubMed     Text format     Abstract available


  26. LUO C, Shen J
    Research progress in advanced melanoma.
    Cancer Lett. 2017 Apr 3. pii: S0304-3835(17)30219.
    PubMed     Text format     Abstract available


  27. REN Y, Chen Y, Liang X, Lu Y, et al
    MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3.
    Cancer Lett. 2017;390:126-136.
    PubMed     Text format     Abstract available


    March 2017
  28. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    PubMed     Text format     Abstract available


  29. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    PubMed     Text format     Abstract available


  30. ANDL T, Zhou L, Yang K, Kadekaro AL, et al
    YAP and WWTR1: New targets for skin cancer treatment.
    Cancer Lett. 2017 Mar 7. pii: S0304-3835(17)30154.
    PubMed     Text format     Abstract available


  31. LI Y, Li J, Zhang Y, Wang Y, et al
    Roles of Cancer/Testis Antigens (CTAs) in Breast Cancer.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30148.
    PubMed     Text format     Abstract available


    February 2017
  32. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Text format     Abstract available


  33. BURNETT JP, Lim G, Li Y, Shah RB, et al
    Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Cancer Lett. 2017 Feb 27. pii: S0304-3835(17)30132.
    PubMed     Text format     Abstract available


  34. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Text format     Abstract available


  35. ZHANG Z, Zhu Y, Wang Z, Zhang T, et al
    Yin-Yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30108.
    PubMed     Text format     Abstract available


  36. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Text format     Abstract available


  37. YUAN B, Ye N, Song SS, Wang YT, et al
    Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Cancer Lett. 2017;386:47-56.
    PubMed     Text format     Abstract available


    January 2017
  38. BELGUISE K, Cherradi S, Sarr A, Boissiere F, et al
    PKCtheta-induced phosphorylations control the ability of Fra-1 to stimulate gene expression and cancer cell migration.
    Cancer Lett. 2017;385:97-107.
    PubMed     Text format     Abstract available


  39. WANG H, Sun W
    CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation.
    Cancer Lett. 2017;385:137-143.
    PubMed     Text format     Abstract available


  40. MONTAGNA E, Palazzo A, Maisonneuve P, Cancello G, et al
    Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Cancer Lett. 2017 Jan 26. pii: S0304-3835(17)30068.
    PubMed     Text format     Abstract available


  41. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Text format     Abstract available


  42. RESZKA E, Przybek M, Muurlink O, Peplonska B, et al
    Circadian gene variants and breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30035.
    PubMed     Text format     Abstract available


  43. BUI QT, Im JH, Jeong SB, Kim YM, et al
    Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30037.
    PubMed     Text format     Abstract available


  44. MUNZONE E, Colleoni M
    Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30026.
    PubMed     Text format     Abstract available


  45. MENDOZA-RODRIGUEZ M, Romero HA, Fuentes-Panana EM, Ayala-Sumuano JT, et al
    IL-1beta induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30025.
    PubMed     Text format     Abstract available


  46. HUANG R, Yu Y, Zong X, Li X, et al
    Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1alpha.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30020.
    PubMed     Text format     Abstract available


  47. ESNER M, Graifer D, Lleonart ME, Lyakhovich A, et al
    Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition.
    Cancer Lett. 2017;384:60-69.
    PubMed     Text format     Abstract available


    November 2016
  48. KIM JY, Lee N, Kim YJ, Cho Y, et al
    Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
    Cancer Lett. 2016 Nov 25. pii: S0304-3835(16)30710.
    PubMed     Text format     Abstract available


  49. ZYSK A, DeNichilo MO, Panagopoulos V, Zinonos I, et al
    Adoptive transfer of ex vivo expanded Vgamma9Vdelta2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Cancer Lett. 2016 Nov 16. pii: S0304-3835(16)30699.
    PubMed     Text format     Abstract available


  50. LIANG YK, Zeng, Xiao YS, Wu Y, et al
    MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERalpha expression and AKT activation.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30682.
    PubMed     Text format     Abstract available


  51. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30681.
    PubMed     Text format     Abstract available


  52. JI X, Peng Z, Li X, Yan Z, et al
    Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
    Cancer Lett. 2016 Nov 7. pii: S0304-3835(16)30662.
    PubMed     Text format     Abstract available


    October 2016
  53. WANG X, Wei S, Zhao Y, Shi C, et al
    Anti-proliferation of breast cancer cells with itraconazole: hedgehog pathway inhibition induces apoptosis and autophagic cell death.
    Cancer Lett. 2016 Oct 31. pii: S0304-3835(16)30665.
    PubMed     Text format     Abstract available


  54. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Text format     Abstract available


  55. VENNIN C, Spruyt N, Robin YM, Chassat T, et al
    The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30644.
    PubMed     Text format     Abstract available


  56. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Text format     Abstract available


  57. KIKUCHI M, Katoh H, Waraya M, Tanaka Y, et al
    Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
    Cancer Lett. 2016 Oct 15. pii: S0304-3835(16)30629.
    PubMed     Text format     Abstract available


  58. MIMOTO R, Nihira NT, Hirooka S, Takeyama H, et al
    Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30627.
    PubMed     Text format     Abstract available


    September 2016
  59. XU P, Dang Y, Wang L, Liu X, et al
    Lgr4 is crucial for skin carcinogenesis by regulating MEK/ERK and Wnt/beta-catenin signaling pathways.
    Cancer Lett. 2016 Sep 29. pii: S0304-3835(16)30547.
    PubMed     Text format     Abstract available


  60. TYAGI N, Srivastava SK, Arora S, Omar Y, et al
    Comparative analysis of the relative potential of silver, Zinc-oxide and titanium-dioxide nanoparticles against UVB-induced DNA damage for the prevention of skin carcinogenesis.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30568.
    PubMed     Text format     Abstract available


  61. XU J, Han M, Shen J, Guan Q, et al
    2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30553.
    PubMed     Text format     Abstract available


  62. DI MODICA M, Regondi V, Sandri M, Iorio MV, et al
    Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30555.
    PubMed     Text format     Abstract available


  63. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Text format     Abstract available


  64. ZHANG Y, Zhang J, Liu C, Du S, et al
    Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Cancer Lett. 2016 Sep 2. pii: S0304-3835(16)30511.
    PubMed     Text format     Abstract available


    July 2016
  65. XU S, Wang H, Pan H, Shi Y, et al
    ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.
    Cancer Lett. 2016 Jul 25. pii: S0304-3835(16)30441.
    PubMed     Text format     Abstract available


    June 2016
  66. BAPU D, Runions J, Kadhim M, Brooks SA, et al
    N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells: A role for truncated O-glycans in metastatic mechanisms.
    Cancer Lett. 2016;375:367-74.
    PubMed     Text format     Abstract available


  67. CHEN KH, Walker AM
    Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Cancer Lett. 2016;375:293-302.
    PubMed     Text format     Abstract available


    May 2016
  68. LU Y, Wang Y, Miao L, Haynes M, et al
    Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Cancer Lett. 2016 May 25. pii: S0304-3835(16)30338.
    PubMed     Text format     Abstract available


  69. BETTI M, Aspesi A, Biasi A, Casalone E, et al
    CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Cancer Lett. 2016 May 12. pii: S0304-3835(16)30306.
    PubMed     Text format     Abstract available


  70. NUTA O, Somaiah N, Boyle S, Chua ML, et al
    Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
    Cancer Lett. 2016;374:324-30.
    PubMed     Text format     Abstract available


    April 2016
  71. REN Y, Zhou X, Liu X, Jia HH, et al
    Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
    Cancer Lett. 2016;374:96-106.
    PubMed     Text format     Abstract available


  72. LIU B, Zhang X, Song F, Zheng H, et al
    Mir-502/SET8 regulatory circuit in pathobiology of breast cancer.
    Cancer Lett. 2016 Apr 11. pii: S0304-3835(16)30221.
    PubMed     Text format     Abstract available


  73. MA XJ, Shang L, Zhang WM, Wang MR, et al
    Mitotic regulator Nlp interacts with XPA/ERCC1 complexes and regulates nucleotide excision repair (NER) in response to UV radiation.
    Cancer Lett. 2016;373:214-21.
    PubMed     Text format     Abstract available


  74. YU C, Tang W, Wang Y, Shen Q, et al
    Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30219.
    PubMed     Text format     Abstract available


  75. WU J, Zhang S, Shan J, Hu Z, et al
    Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30218.
    PubMed     Text format     Abstract available


  76. LIANG DH, Choi DS, Ensor JE, Kaipparettu BA, et al
    The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30215.
    PubMed     Text format     Abstract available


  77. MALTONI R, Gallerani G, Fici P, Rocca A, et al
    CTCs in early breast cancer: A path worth taking.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30212.
    PubMed     Text format     Abstract available


  78. MALEVA KOSTOVSKA I, Wang J, Bogdanova N, Schurmann P, et al
    Rare ATAD5 missense variants in breast and ovarian cancer patients.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30209.
    PubMed     Text format     Abstract available


    March 2016
  79. LIU J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, et al
    GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30198.
    PubMed     Text format     Abstract available


  80. RIGALLI JP, Tocchetti GN, Arana MR, Villanueva SS, et al
    The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
    Cancer Lett. 2016 Mar 23. pii: S0304-3835(16)30200.
    PubMed     Text format     Abstract available


  81. BRANTLEY E, Callero MA, Berardi DE, Campbell P, et al
    AhR ligand Aminoflavone inhibits alpha6-integrin expression and breast cancer sphere-initiating capacity.
    Cancer Lett. 2016 Mar 17. pii: S0304-3835(16)30175.
    PubMed     Text format     Abstract available


  82. AMPUJA M, Alarmo EL, Owens P, Havunen R, et al
    The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.
    Cancer Lett. 2016 Mar 9. pii: S0304-3835(16)30145.
    PubMed     Text format     Abstract available


  83. GOBEL A, Thiele S, Browne AJ, Rauner M, et al
    Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2016 Mar 8. pii: S0304-3835(16)30140.
    PubMed     Text format     Abstract available


  84. LV W, Chen N, Lin Y, Ma Y, et al
    Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis.
    Cancer Lett. 2016 Mar 4. pii: S0304-3835(16)30051.
    PubMed     Text format     Abstract available


  85. ROWSON-HODEL AR, Berg AL, Wald JH, Hatakeyama J, et al
    Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
    Cancer Lett. 2016 Mar 2. pii: S0304-3835(16)30120.
    PubMed     Text format     Abstract available


  86. JACOB J, Favicchio R, Karimian N, Mehrabi M, et al
    LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
    Cancer Lett. 2016;372:137-46.
    PubMed     Text format     Abstract available


  87. JAKHAR R, Paul S, Bhardwaj M, Kang SC, et al
    Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis.
    Cancer Lett. 2016;372:89-100.
    PubMed     Text format     Abstract available


  88. XU Z, Wang Z, Jia X, Wang L, et al
    MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Cancer Lett. 2016;372:118-27.
    PubMed     Text format     Abstract available


    February 2016
  89. KIM PY, Tan O, Liu B, Trahair T, et al
    High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.
    Cancer Lett. 2016 Feb 19. pii: S0304-3835(16)30075.
    PubMed     Text format     Abstract available


  90. KAWPRASERTSRI S, Pietras RJ, Marguez-Garban DC, Boonyaratanakornkit V, et al
    Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.
    Cancer Lett. 2016 Feb 15. pii: S0304-3835(16)30068.
    PubMed     Text format     Abstract available


  91. GREK CL, Rhett JM, Bruce JS, Ghatnekar GS, et al
    Connexin 43, breast cancer tumor suppressor: missed connections?
    Cancer Lett. 2016 Feb 13. pii: S0304-3835(16)30062.
    PubMed     Text format     Abstract available


    January 2016
  92. AMOURY M, Kolberg K, Pham AT, Hristodorov D, et al
    Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Cancer Lett. 2016 Jan 21. pii: S0304-3835(16)00039.
    PubMed     Text format     Abstract available


  93. LUO M, Hou L, Li J, Shao S, et al
    VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin.
    Cancer Lett. 2016 Jan 19. pii: S0304-3835(16)00022.
    PubMed     Text format     Abstract available


  94. SHARMA MC, Tuszynski GP, Blackman MR, Sharma M, et al
    Long-term efficacy and downstream mechanism of anti-annexina2 monoclonal antibody (anti-ANX a2 mAb) in a pre-clinical model of aggressive human breast cancer.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00025.
    PubMed     Text format     Abstract available


  95. SHARMA B, Varney ML, Saxena S, Wu L, et al
    Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00750.
    PubMed     Text format     Abstract available


  96. SUYAMA K, Onishi H, Imaizumi A, Shinkai K, et al
    CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00754.
    PubMed     Text format     Abstract available


    December 2015
  97. LEE DH, Jung Jung Y, Koh D, Lim Y, et al
    A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells.
    Cancer Lett. 2015 Dec 29. pii: S0304-3835(15)00768.
    PubMed     Text format     Abstract available


  98. HUNG AC, Tsai CH, Hou MF, Chang WL, et al
    The synthetic beta-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
    Cancer Lett. 2015 Dec 9. pii: S0304-3835(15)00725.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: